| 24.585 1.245 (5.33%) | 11-14 13:13 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 31.41 | 1-year : | 36.69 |
| Resists | First : | 26.89 | Second : | 31.41 |
| Pivot price | 24.24 |
|||
| Supports | First : | 22.36 |
Second : | 19.55 |
| MAs | MA(5) : | 23.76 |
MA(20) : | 23.71 |
| MA(100) : | 17.58 |
MA(250) : | 13.97  |
|
| MACD | MACD : | 0.9 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 44 |
D(3) : | 43.8 |
| RSI | RSI(14): 60 |
|||
| 52-week | High : | 26.89 | Low : | 5.13 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ UPB ] has closed below upper band by 43.6%. Bollinger Bands are 23.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 24 - 24.16 | 24.16 - 24.3 |
| Low: | 22.68 - 22.84 | 22.84 - 22.96 |
| Close: | 23.11 - 23.36 | 23.36 - 23.57 |
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
Thu, 06 Nov 2025
Upstream Bio Reports Progress in Respiratory Trials - TipRanks
Thu, 06 Nov 2025
Decoding Upstream Bio Inc (UPB): A Strategic SWOT Insight - GuruFocus
Wed, 05 Nov 2025
Earnings Flash (UPB) Upstream Bio, Inc. Reports Q3 Revenue $683,000 - MarketScreener
Wed, 05 Nov 2025
Upstream Bio, Inc. SEC 10-Q Report - TradingView
Wed, 05 Nov 2025
Upstream Bio (NASDAQ: UPB) VIBRANT Phase 2 CRSwNP: -1.8 NPS with dosing every 12 weeks - Stock Titan
Wed, 05 Nov 2025
Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 54 (M) |
| Held by Insiders | 3.142e+007 (%) |
| Held by Institutions | 14.8 (%) |
| Shares Short | 3,010 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.2142e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 732.8 % |
| Return on Equity (ttm) | -22.9 % |
| Qtrly Rev. Growth | 2.72e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -6.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -114 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 3.34e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|